VRDN — Viridian Therapeutics, Inc.\DE
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1590750 ·
Last close
$24.02
Market Cap
$2.72B
52W High
$24.86
52W Low
$15.50
ADV30
1,787,330
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 284,000 | — | -126,268,000 | -127,119,000 | 1,097,233,000 | 164,986,000 | 435,136,000 |
| Mar 2026 | 141,000 | — | -116,169,000 | -104,901,000 | 789,017,000 | 176,346,000 | 153,009,000 |
| Dec 2025 | 132,000 | — | -122,749,000 | -120,355,000 | 899,418,000 | 212,382,000 | 177,251,000 |
| Sep 2025 | 70,570,000 | — | -40,013,000 | -34,599,000 | 577,138,000 | 169,647,000 | 74,168,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-333,343,000
Investing CF
$-367,239,000
Financing CF
$748,244,000
CapEx
$-1,696,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.37
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,570,478,000
Inventory
—
Receivables
$75,000,000
ST Investments
$816,544,000
EBIT TTM
$-371,363,000
Pretax Income TTM
$-386,974,000
Interest Exp TTM
$15,611,000
Analysts
16
Yahoo Snapshot (yfinance, live)
Total Revenue
$71,127,000
EBITDA
$-404,731,008
Free Cash Flow
$-275,496,000
Enterprise Value
$2,113,095,168
Total Cash
$981,529,984
Total Debt
$244,732,000
Shares Out
113,292,269
Trailing EPS
$-3.40
Book Value
$4.92
ROE
-65.7%
ROA
-30.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 70,849,000 | -363,395,000 | -342,601,000 | 899,418,000 | 177,251,000 | — | -276,391,000 |
| Dec 2024 | 302,000 | -299,035,000 | -269,949,000 | 742,403,000 | 70,764,000 | — | -232,319,000 |
| Dec 2023 | 314,000 | -254,450,000 | -237,734,000 | 490,424,000 | 48,402,000 | — | -184,170,000 |
| Dec 2022 | 1,772,000 | -134,304,000 | -129,874,000 | 435,091,000 | 40,027,000 | — | -93,838,000 |
TTM Snapshot
Revenues TTM
$1,561,000
NetIncome TTM
$-167,297,000
OpCashFlow TTM
$0
Assets (Latest)
$742,403,000
Forward EPS
$-2.77
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $16.00 · spot: $24.02 · call volume: 399 · put volume: 64
Expected Move to 2026-10-16:
±$4.50
(18.73%) —
implied range
$19.52 –
$28.52
· ATM straddle on $24.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | $2.73B | $26.27 | — |
| ATAI | AtaiBeckley Inc. | $2.74B | $7.38 | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.62B | $45.11 | — |
| PHVS | Pharvaris N.V. | $2.62B | $37.31 | — |
| TRVI | Trevi Therapeutics, Inc. | $2.58B | $18.08 | — |
News headlines (Yahoo Finance, 1h cache)
Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says
2026-08-07 16:05 · Yahoo
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
2026-08-06 11:01 · Yahoo
Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)
2026-07-15 14:01 · Yahoo
Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich?
2026-07-15 12:24 · Yahoo
Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today
2026-07-15 05:10 · Yahoo
Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone
2026-07-06 17:21 · Yahoo
Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says
2026-06-30 15:53 · Yahoo
Comcast, Viridian Therapeutics jump premarket; Doximity slips
2026-06-29 12:09 · Yahoo
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval
2026-06-26 22:57 · Yahoo
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
2026-06-26 22:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.